Advances in Studying the Pathologic Mechanisms and Treatment Strategies of Transthyretin Amyloidosis.

IF 2.2 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Journal of Cardiovascular Pharmacology Pub Date : 2025-03-01 DOI:10.1097/FJC.0000000000001663
Hongyin Chen, Ruonan Liu, Siqi Luo, Jinzi Su
{"title":"Advances in Studying the Pathologic Mechanisms and Treatment Strategies of Transthyretin Amyloidosis.","authors":"Hongyin Chen, Ruonan Liu, Siqi Luo, Jinzi Su","doi":"10.1097/FJC.0000000000001663","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Transthyretin amyloidosis (ATTR) is characterized by the deposition of unstable transthyretin protein (TTR) in the heart or peripheral nerves. Therapeutic strategies for ATTR include inhibition of the secretion of abnormal TTR by the liver, reducing the concentration of aberrant TTR in the circulation, and eliminating amyloid deposits of TTR in tissues. This article delves into the pathogenesis of TTR secretion from the liver into the bloodstream, its deposition in tissues, and the subsequent development of ATTR. In addition, we delineated the advancements in treatment strategies and discussed future research directions to provide novel insights for the identification of diagnostic and preventive targets.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"186-193"},"PeriodicalIF":2.2000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/FJC.0000000000001663","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract: Transthyretin amyloidosis (ATTR) is characterized by the deposition of unstable transthyretin protein (TTR) in the heart or peripheral nerves. Therapeutic strategies for ATTR include inhibition of the secretion of abnormal TTR by the liver, reducing the concentration of aberrant TTR in the circulation, and eliminating amyloid deposits of TTR in tissues. This article delves into the pathogenesis of TTR secretion from the liver into the bloodstream, its deposition in tissues, and the subsequent development of ATTR. In addition, we delineated the advancements in treatment strategies and discussed future research directions to provide novel insights for the identification of diagnostic and preventive targets.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
转甲状腺素淀粉样变的病理机制及治疗策略研究进展。
甲状腺转蛋白淀粉样变性(ATTR)的特征是不稳定的甲状腺转蛋白(TTR)在心脏或周围神经沉积。ATTR的治疗策略包括抑制肝脏分泌异常TTR,降低循环中异常TTR的浓度,消除组织中TTR的淀粉样沉积。本文就肝脏分泌TTR进入血流的发病机制、TTR在组织中的沉积以及ATTR的后续发展进行了探讨。此外,我们描述了治疗策略的进展,并讨论了未来的研究方向,为诊断和预防靶点的确定提供了新的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.10
自引率
3.30%
发文量
367
审稿时长
1 months
期刊介绍: Journal of Cardiovascular Pharmacology is a peer reviewed, multidisciplinary journal that publishes original articles and pertinent review articles on basic and clinical aspects of cardiovascular pharmacology. The Journal encourages submission in all aspects of cardiovascular pharmacology/medicine including, but not limited to: stroke, kidney disease, lipid disorders, diabetes, systemic and pulmonary hypertension, cancer angiogenesis, neural and hormonal control of the circulation, sepsis, neurodegenerative diseases with a vascular component, cardiac and vascular remodeling, heart failure, angina, anticoagulants/antiplatelet agents, drugs/agents that affect vascular smooth muscle, and arrhythmias. Appropriate subjects include new drug development and evaluation, physiological and pharmacological bases of drug action, metabolism, drug interactions and side effects, application of drugs to gain novel insights into physiology or pathological conditions, clinical results with new and established agents, and novel methods. The focus is on pharmacology in its broadest applications, incorporating not only traditional approaches, but new approaches to the development of pharmacological agents and the prevention and treatment of cardiovascular diseases. Please note that JCVP does not publish work based on biological extracts of mixed and uncertain chemical composition or unknown concentration.
期刊最新文献
Sphingosine-1-Phosphate/Protein Kinase Cβ2 Signaling Mediates Hypercontraction of Mesenteric Arterial Smooth Muscle in Spontaneously Hypertensive Rats. Cardioprotective effects of prophylactic ACE inhibitors in anthracycline-induced cardiotoxicity: a systematic review and meta-analysis of randomized trials. The more the lipid lowering agents, the merrier: welcome to combination therapy with cholesteryl ester transfer protein inhibitors! The Multifaceted Role of Angiopoietin-Like Proteins in Coronary Heart Disease: From Molecular Mechanisms to Clinical Translation. Diurnal rhythm in blood pressure is preserved in hypertensive mice despite therapy with mineralocorticoid receptor antagonists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1